AHMED HASSAN ELNAGGAR

Dynamic Senior Regional Medical Advisor with Novo Nordisk A/S, adept at driving impactful medical support and education initiatives. Proven expertise in healthcare insights and compliance, fostering strong relationships with key stakeholders. Recognized for enhancing team collaboration and implementing successful programs that elevate clinician engagement and patient care.

• Board certified medical affairs professional.
• On boarding Medical advisor online training.
• Biostatistics.

• Extensive experience spanning nineteen years in multinational pharmaceuticals, with involvement in product launches and company mergers.
• Fifteen years of in-depth exposure to the gulf market segments, including MOH, Institution & Private, the largest in the Middle East.
• Board Certified Medical Affairs Specialist graduate.
• Deep understanding of medical research, clinical trials, and product knowledge to provide accurate medical insights and guidance.
• Ability to develop and implement strategic initiatives that align with business objectives and patient needs.
• Committed to understanding and addressing patient needs to improve overall health outcomes and experiences.
• Effective communicator with strong presentation skills, capable of building relationships with key stakeholders including healthcare professionals.
• Familiarity with healthcare regulations and ability to ensure compliance in all medical activities.
• Proficient in analyzing data and generating insights to support evidence-based decision making.
• Skilled in designing and delivering educational programs to inform and empower healthcare teams and stakeholders.
• Creative thinker with a proactive approach to solving complex medical and logistical challenges.
• Demonstrated ability to work seamlessly within cross-functional teams.
• Date of Birth: 09/11/84
• Nationality: Egyptian-American
• Marital Status: Married with three children

· Successfully designed and obtained approval for an adherence study for Somapacitan, strategically addressing and filling a critical gap in patient care.

· Initiated and led innovative screening projects for inhibitors, Genetic Testing (GT), and IGF-1 levels, reinforcing a commitment to addressing unmet patient needs and enhancing outcomes.

· Demonstrated a patient-centric approach by prioritizing initiatives that elevate the standard of care and improve patient experiences, further aligning with patient-focused strategies.

· Orchestrated pre-launch and launch plans for Turoctocog alfa – Novoeight®, Turoctocog alfa Pegol – Esperoct®, and Somapacitan – Sogroya® successfully.

· Ran the first KSA Haemophilia Advisory Board, contributing to the advancement of treatment awareness and collaboration among healthcare professionals.

· Developed new non-promotional educational materials (screening diaries, haemophilia cards, patient booklets) to enhance patient knowledge and engagement

· Planning and successful execution of speaker tours in the gulf with the objective of raising the awareness of the treating physicians about the unmet medical needs in the Haemophilia & RBDs therapy area.

· Developing new way of Organizational readiness ( Did you Know ? & Medical competition )

· 2015 NovoSeven Best achiever.

· Best Global Biopharm unit 2011, 2014

• Arabic (Mother tongue)
• English (Fluent)

Available upon request.